Myocardial infarction: genes and variants
Explore variant evidence for Myocardial infarction across 23 analyzed proteins (F7, ITGB3, ACE, AGTR1, APOA5 and 18 more). Linked ClinVar records include 5 pathogenic or likely pathogenic variants, 4 variants of uncertain significance and 0 with conflicting classifications.
Coverage includes proteins already analyzed in CATVariant, not every gene involved in this condition. Database links are associations, not an assessment of clinical gene–disease validity. Computable evidence prioritizes variants for expert review and does not reclassify them. Source labels are pooled across this disease family.
Data updated 2026-10-21. Automated aggregation, not a clinical review date.
Download variant evidence (CSV)
Genes linked to Myocardial infarction
F7: Coagulation factor VII
It binds tissue factor at sites of vascular injury and initiates coagulation by activating factors IX and X. Biallelic deficiency causes a rare bleeding disorder with highly variable severity, while recombinant activated factor VII is used therapeutically in selected bleeding conditions.
5 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in F7 have source records linked to Myocardial infarction. Association strength is not clinical gene validity.
ITGB3: Integrin beta-3
In platelets it pairs with ITGA2B to bind fibrinogen and mediate aggregation, while in other cells it forms integrins involved in matrix adhesion and signaling. Biallelic loss-of-function variants cause Glanzmann thrombasthenia.
0 ClinVar pathogenic / likely pathogenic and 2 uncertain variants in ITGB3 have source records linked to Myocardial infarction. Association strength is not clinical gene validity.
ACE: Angiotensin-converting enzyme
A membrane-associated enzyme that removes terminal dipeptides from hormones and signaling peptides, including angiotensin I and bradykinin. By generating angiotensin II and inactivating vasodilators, it helps regulate blood pressure, fluid balance, and aspects of nervous-system signaling.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in ACE have source records linked to Myocardial infarction. Association strength is not clinical gene validity.
AGTR1: Type-1 angiotensin II receptor
Its activation by angiotensin II promotes vasoconstriction, aldosterone release, sodium retention, and vascular remodeling. Excessive signaling contributes to hypertension and cardiovascular disease, and the pathway is therapeutically blocked by angiotensin-receptor blockers.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in AGTR1 have source records linked to Myocardial infarction. Association strength is not clinical gene validity.
APOA5: Apolipoprotein A-V
It strongly modulates plasma triglyceride levels by promoting efficient clearance of triglyceride-rich lipoproteins. Rare loss-of-function variants can cause severe hypertriglyceridemia and increase susceptibility to familial chylomicronemia-like phenotypes and pancreatitis.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in APOA5 have source records linked to Myocardial infarction. Association strength is not clinical gene validity.
APOB: Apolipoprotein B-100
It provides the structural backbone for triglyceride-rich lipoproteins and LDL, while ApoB-100 also mediates LDL-receptor binding and clearance. Pathogenic variants can cause familial hypobetalipoproteinemia or defective ApoB-related hypercholesterolemia depending on their effect on particle assembly and receptor binding.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in APOB have source records linked to Myocardial infarction. Association strength is not clinical gene validity.
APOE: Apolipoprotein E
It redistributes cholesterol and other lipids between tissues by directing remnant lipoproteins to LDL-receptor-family members. The common epsilon4 isoform strongly increases late-onset Alzheimer disease risk and also influences plasma lipids and cardiovascular risk.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in APOE have source records linked to Myocardial infarction. Association strength is not clinical gene validity.
CACNA1C: Voltage-dependent L-type calcium channel subunit alpha-1C
Its opening provides a major source of depolarization-triggered calcium entry in cardiomyocytes, smooth muscle, and neurons, coupling electrical activity to contraction and signaling. Pathogenic variants can cause Timothy syndrome, Brugada or long-QT phenotypes, and several neurodevelopmental disorders.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in CACNA1C have source records linked to Myocardial infarction. Association strength is not clinical gene validity.
CACNA1D: Voltage-dependent L-type calcium channel subunit alpha-1D
It supports calcium entry in endocrine cells, neurons, and cardiac pacemaker tissue, influencing hormone secretion, neuronal excitability, and sinoatrial activity. Activating variants can cause primary aldosteronism with seizures and neurologic abnormalities, while other variants cause neurodevelopmental or hearing phenotypes.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in CACNA1D have source records linked to Myocardial infarction. Association strength is not clinical gene validity.
CACNA1S: Voltage-dependent L-type calcium channel subunit alpha-1S
Its voltage sensing in skeletal-muscle transverse tubules mechanically activates RYR1 and couples membrane depolarization to sarcoplasmic-reticulum calcium release. Pathogenic variants can cause hypokalemic periodic paralysis, malignant-hyperthermia susceptibility, and congenital myopathy.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in CACNA1S have source records linked to Myocardial infarction. Association strength is not clinical gene validity.
HMGCR: 3-hydroxy-3-methylglutaryl-coenzyme A reductase
It controls the rate-limiting step of the mevalonate pathway and therefore strongly regulates endogenous cholesterol production. Statins lower LDL cholesterol by inhibiting this activity, causing the liver to increase LDL-receptor-mediated clearance from blood.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in HMGCR have source records linked to Myocardial infarction. Association strength is not clinical gene validity.
ITGA2B: Integrin alpha-IIb
Together with ITGB3, it forms the major platelet fibrinogen receptor that becomes activated during platelet stimulation and drives aggregation. Biallelic loss-of-function variants cause Glanzmann thrombasthenia, a severe inherited platelet-aggregation disorder.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in ITGA2B have source records linked to Myocardial infarction. Association strength is not clinical gene validity.
LDLR: Low-density lipoprotein receptor
It removes ApoB-containing LDL particles from the circulation through receptor-mediated endocytosis, especially in hepatocytes. Loss-of-function variants are the most common cause of familial hypercholesterolemia and lead to lifelong LDL elevation and premature atherosclerotic disease.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in LDLR have source records linked to Myocardial infarction. Association strength is not clinical gene validity.
LPA: Apolipoprotein(a)
Its apolipoprotein(a) component covalently attaches to an LDL-like particle to form lipoprotein(a), whose circulating level is largely genetically determined. High Lp(a) is a causal risk factor for atherosclerotic cardiovascular disease and calcific aortic-valve disease.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in LPA have source records linked to Myocardial infarction. Association strength is not clinical gene validity.
LPL: Lipoprotein lipase
It hydrolyzes triglycerides in circulating chylomicrons and very-low-density lipoproteins so tissues can take up released fatty acids. Severe biallelic loss causes familial chylomicronemia, while common variation strongly influences triglyceride levels and cardiovascular risk.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in LPL have source records linked to Myocardial infarction. Association strength is not clinical gene validity.
PCSK9: Proprotein convertase subtilisin/kexin type 9
By binding hepatic LDL receptors and promoting their lysosomal degradation, it reduces receptor recycling and raises circulating LDL cholesterol. Gain-of-function variants cause autosomal dominant hypercholesterolemia, whereas loss-of-function variants lower LDL cholesterol and cardiovascular risk.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in PCSK9 have source records linked to Myocardial infarction. Association strength is not clinical gene validity.
PLAT: Tissue-type plasminogen activator
It converts plasminogen to plasmin preferentially on fibrin surfaces, promoting breakdown of established blood clots. Recombinant tissue plasminogen activator is used therapeutically for selected acute ischemic strokes and thrombotic emergencies, balanced against bleeding risk.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in PLAT have source records linked to Myocardial infarction. Association strength is not clinical gene validity.
SERPINC1: Antithrombin-III
It neutralizes thrombin and several activated coagulation proteases and is greatly accelerated by heparin-like molecules. Heterozygous deficiency causes a strong inherited predisposition to venous thrombosis and can reduce responsiveness to heparin.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in SERPINC1 have source records linked to Myocardial infarction. Association strength is not clinical gene validity.
SH2B3: SH2B adapter protein 3
It restrains cytokine and growth-factor signaling in hematopoietic cells, including JAK-STAT pathways controlling blood-cell production. Loss-of-function variants can increase blood-cell proliferation and predispose to myeloproliferative neoplasms, while common variants influence autoimmune and hematologic traits.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in SH2B3 have source records linked to Myocardial infarction. Association strength is not clinical gene validity.
SLC12A3: Solute carrier family 12 member 3
It reabsorbs sodium and chloride in the distal convoluted tubule and is a major determinant of renal salt and magnesium handling. Biallelic loss-of-function variants cause Gitelman syndrome with hypokalemic metabolic alkalosis, hypomagnesemia, and low urinary calcium.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in SLC12A3 have source records linked to Myocardial infarction. Association strength is not clinical gene validity.
TUBB2B: Tubulin beta-2B chain
It contributes to neuronal microtubules needed for progenitor division, neuronal migration, axon development, and cortical organization. Heterozygous pathogenic variants cause tubulinopathy with polymicrogyria, cortical dysplasia, developmental delay, and sometimes epilepsy.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in TUBB2B have source records linked to Myocardial infarction. Association strength is not clinical gene validity.
TUBB3: Tubulin beta-3 chain
It forms neuronal microtubules required for axon growth, guidance, and intracellular transport. Heterozygous pathogenic variants can cause congenital fibrosis of the extraocular muscles type 3 and broader tubulinopathy phenotypes with brain and cranial-nerve abnormalities.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in TUBB3 have source records linked to Myocardial infarction. Association strength is not clinical gene validity.
VKORC1: Vitamin K epoxide reductase complex subunit 1
It recycles vitamin K to support gamma-carboxylation of coagulation proteins and is the direct pharmacologic target of warfarin. Common variants strongly influence warfarin dose requirements, while rare variants can cause warfarin resistance or vitamin-K-dependent clotting-factor deficiency.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in VKORC1 have source records linked to Myocardial infarction. Association strength is not clinical gene validity.
Weakly linked (only a few uncertain records): F13A1 and CLCN1.
ClinVar pathogenic and likely pathogenic variants linked to Myocardial infarction
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| F7 R364W | 364 | Peptidase S1 | Pathogenic / likely pathogenic (★★) |
| F7 R364Q | 364 | Peptidase S1 | Pathogenic / likely pathogenic (★★) |
| F7 A429T | 429 | Peptidase S1 | Pathogenic / likely pathogenic (★★) |
| F7 A354V | 354 | Peptidase S1 | Pathogenic / likely pathogenic (★★) |
| F7 A304V | 304 | Peptidase S1 | Pathogenic / likely pathogenic (★★) |
Same protein, different disease
- Factor VII deficiency also has ClinVar records linked to F7 variants; they fall mostly in different places as the Myocardial infarction variants (8 pathogenic / likely pathogenic).
Diseases related to Myocardial infarction
- Diabetes mellitus, also linked to ACE, AGTR1, APOE, CACNA1C and 2 more
- Familial hypercholesterolemia, also linked to APOB, APOE, HMGCR, LDLR and 1 more
- Type 2 diabetes mellitus, also linked to ACE, AGTR1, APOE, HMGCR and 1 more
- Hyperlipoproteinemia, also linked to APOA5, APOE, HMGCR and LPL
- Alzheimer disease, also linked to ACE, APOE and HMGCR
- Homozygous familial hypercholesterolemia, also linked to APOB, LDLR and PCSK9
- Epilepsy, also linked to CACNA1C, CACNA1D and CACNA1S
- Heart disease, also linked to LDLR, LPA and PCSK9
- Hypertrophic cardiomyopathy, also linked to ITGA2B and ITGB3
- Noonan syndrome, also linked to ITGA2B and ITGB3
- Glanzmann thrombasthenia, also linked to ITGA2B and ITGB3
- Complex cortical dysplasia with other brain malformations, also linked to TUBB2B and TUBB3
Frequently asked questions
Which genes have records linked to Myocardial infarction?
This view contains 23 analyzed proteins: F7, ITGB3, ACE, AGTR1, APOA5 and 18 more. Links come from clinical records and association databases. They do not imply that every listed gene is a validated cause, and missing genes may not yet be analyzed.
What do the clinical classifications mean?
Linked records include 5 pathogenic or likely pathogenic variants, 4 variants of uncertain significance and 0 with conflicting classifications. Labels summarize source records; multi-condition records may not make a separate assertion for this disease. Check the original record and review status.
Does the evidence score change a VUS classification?
No. 0 VUS or conflicting variants reach the likely-pathogenic points range on the computable criteria available here. This is a research prioritization signal, not a clinical classification. Patient, family and other required evidence may be missing.
Can I download the variant evidence?
Download the CSV for all 10 variants in the selected disease scope, including clinical labels, review status, evidence criteria, predictor scores, functional measurements and population frequency where available.
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from eligible public CATVariant analyses of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center